Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Mcgill University
Headquarters: Montreal, QC, Canada
Website: http://www.mcgill.ca
Year Founded: 1821
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Nov 29, 2023
Distillery Therapeutics
Small molecule NRF2 inhibitor for KEAP1-mutant lung cancer
BioCentury | Aug 11, 2023
Discovery & Translation
Bacteria to detect tumors; plus Netris’ mAb to block EMT in cancer and more
BioCentury’s roundup of translational innovations
BioCentury | Feb 9, 2022
Discovery & Translation
Translational trendspotting: a Distillery dive into infectious disease
Host targets, cross-reactive mAbs and COVID-19 countermeasures stand out in BioCentury’s Distillery
BioCentury | Sep 10, 2021
Targets & Mechanisms
Integrated stress response key to seemingly disparate diseases?
A flurry of preclinical studies builds the case for the integrated stress response as a central driver of many diseases
BioCentury | Aug 27, 2021
Distillery Therapeutics
Blocking unfolded protein response, integrated stress response for necrotizing fasciitis, lung cancer
BioCentury | Dec 2, 2020
Emerging Company Profile
Sofinnova’s Papiernik, Costa and Roche alum Garibaldi carve orphan neurology play Noema out of the pharma’s assets
Emerging Company Profile: Noema emerges from stealth with $59M to develop four clinical neurology programs in-licensed from Roche
BioCentury | Jun 6, 2020
Product Development
June 5 Quick Takes: Merck, Tetraphase-Melinta, Apeiron, Neurasic, Jounce, Genmab-J&J
BioCentury | Jun 4, 2020
Product Development
WHO restarts hydroxychloroquine testing as drug fails another COVID-19 trial
Editors flag ‘serious’ concerns regarding validity of data in Lancet paper
Items per page:
1 - 10 of 207